Epizyme’s Tazemetostat Faces US FDA Doubts About Efficacy In Epithelioid Sarcoma

 
• By Sue Sutter
Risks verses benefits
US FDA questions about the adequacy of efficacy evidence for tazemetostat come amid concerns about the risk of secondary malignancies. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers